Center Laboratories (TWO:4123) — Market Cap & Net Worth
Market Cap & Net Worth: Center Laboratories (4123)
Center Laboratories (TWO:4123) has a market capitalization of $906.73 Million (NT$28.78 Billion) as of May 4, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #9544 globally and #294 in its home market, demonstrating a -3.70% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Center Laboratories's stock price NT$39.00 by its total outstanding shares 737951147 (737.95 Million). Analyse Center Laboratories (4123) cash flow conversion to see how efficiently the company converts income to cash.
Center Laboratories Market Cap History: 2015 to 2026
Center Laboratories's market capitalization history from 2015 to 2026. Data shows growth from $675.04 Million to $906.73 Million (3.35% CAGR).
Center Laboratories Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Center Laboratories's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.63x
Center Laboratories's market cap is 0.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $675.04 Million | $6.79 Billion | $421.50 Million | 0.10x | 1.60x |
| 2016 | $613.06 Million | $15.04 Billion | $19.45 Million | 0.04x | 31.51x |
| 2017 | $536.42 Million | $19.39 Billion | $250.00 Million | 0.03x | 2.15x |
| 2018 | $803.45 Million | $21.65 Billion | $6.08 Billion | 0.04x | 0.13x |
| 2019 | $833.83 Million | $1.44 Billion | -$203.59 Million | 0.58x | N/A |
| 2020 | $1.03 Billion | $717.04 Million | $3.79 Billion | 1.43x | 0.27x |
| 2021 | $1.01 Billion | $500.11 Million | $1.82 Billion | 2.02x | 0.56x |
| 2022 | $949.31 Million | $767.72 Million | -$575.62 Million | 1.24x | N/A |
| 2023 | $1.00 Billion | $1.39 Billion | -$1.05 Billion | 0.72x | N/A |
| 2024 | $1.02 Billion | $1.62 Billion | -$1.10 Billion | 0.63x | N/A |
Competitor Companies of 4123 by Market Capitalization
Companies near Center Laboratories in the global market cap rankings as of May 4, 2026.
Key companies related to Center Laboratories by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Center Laboratories Historical Marketcap From 2015 to 2026
Between 2015 and today, Center Laboratories's market cap moved from $675.04 Million to $ 906.73 Million, with a yearly change of 3.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$906.73 Million | -6.25% |
| 2025 | NT$967.18 Million | -5.13% |
| 2024 | NT$1.02 Billion | +1.88% |
| 2023 | NT$1.00 Billion | +5.41% |
| 2022 | NT$949.31 Million | -6.09% |
| 2021 | NT$1.01 Billion | -1.74% |
| 2020 | NT$1.03 Billion | +23.37% |
| 2019 | NT$833.83 Million | +3.78% |
| 2018 | NT$803.45 Million | +49.78% |
| 2017 | NT$536.42 Million | -12.50% |
| 2016 | NT$613.06 Million | -9.18% |
| 2015 | NT$675.04 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Center Laboratories was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $906.73 Million USD |
| MoneyControl | $906.73 Million USD |
| MarketWatch | $906.73 Million USD |
| marketcap.company | $906.73 Million USD |
| Reuters | $906.73 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Center Laboratories
Center Laboratories, Inc., a pharmaceutical company, develops, manufactures, and sells pharmaceuticals in Taiwan and internationally. The company offers general medication pharmaceuticals comprising antipyretics and analgesics, bronchodilators, anti-inflammatory preparations, antihistamines, expectorants, narcotic antitussives and expectorants, gastrointestinal preparations, non-narcotic antituss… Read more